



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Wednesday November 30, 2005 | 12:33 pm ET

Signalife Announces Ventrex Meets Production Schedule on Model 100

GREENVILLE, S.C.--(BUSINESS WIRE)--Nov. 30, 2005--Signalife, Inc. (AMEX:SGN - News) announced that the initial manufacture Model 100 Heart Monitor has been completed with commercial quality product delivered ahead of schedule. "The initiation of Signalife's manufacturing capability is the culmination of a successful technology transfer program executed by Signalife and our contract manufacturing partner, Ventrex, Inc. of Ventura, CA," reported William Mathews, responsible for the company's regulatory affairs activities.

The Model 100 Heart Monitor is a patient heart monitor that uses a patented signal-processing technology to record a clinical-quality EKG signal in the presence of interference generated by the patient's body movements and ambient environment. The Model 100, which has received 510(k) clearance from the FDA as an ambulatory heart monitor, will be commercially available for both ambulatory and clinical resting applications. The ambulatory application of the device provides clinical-quality EKG signals even as the patient moves about. "The technology is safe, extremely accurate and easy to utilize," said Dr. Michael I. Weintraub, clinical professor of neurology and internal medicine of New York Medical College and adjunct clinical professor of neurology at Mount Sinai School of Medicine. "This is going to become the standard of care and will allow the physician more data to interpret and detect potential heart irregularities," Weintraub added.

According to Pamela M. Bunes, president and chief executive officer of Signalife, "The manufacture, assembly and delivery of our first commercial Model 100 Heart Monitors represents a significant milestone for Signalife as the company now has the proven ability to manufacture and deliver commercial units to the end user and to facilitate our marketing plans. Signalife will now shift its focus to ramping up its marketing efforts to develop product awareness and knowledge of this new monitoring technology in the medical community. We are currently conducting user preference tests with the limited number of pre-production Model 100 Heart Monitors previously on hand to better identify performance, usability and aesthetic aspects of our system. We will now replace these earlier models being tested with later-generation commercial versions and, in the near future, distribute approximately one hundred additional later-generation models to a large number of leading cardiologists, hospitals, clinics and research institutions who have expressed an interest in using and testing our heart monitor with the ultimate objective of purchasing the product. Since our Model 100 Heart Monitor uses a new signal-processing technology without a medical industry track record, it is necessary for these initial users to have the opportunity to fully test the product for a sufficient period of time before making a purchase decision. We anticipate that we will commence closing sales and generating revenues in the near future. In the meantime, we will also use the feedback given by these initial users to further refine the performance, usability and aesthetic aspects of our system while we continue to build up inventory."

About Signalife

Signalife, formerly Recom Managed Systems, Inc., is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is <http://www.Signalife.com>. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.

Contact:

Signalife

Claire M. LaFrance, 864-233-2300

Caution Regarding Forward-Looking Statements

Statements in this release □
which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences
include, but are not limited □
tory approvals governing medica □
Signalife’s products o □
to complete management’s plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further
described in Signalife’s filings with the Securities and Exchange Commission

###